Quintet Private Bank Europe S.A. reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 90.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,790 shares of the biopharmaceutical company’s stock after selling 33,970 shares during the quarter. Quintet Private Bank Europe S.A.’s holdings in Bristol Myers Squibb were worth $236,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of BMY. Boltwood Capital Management grew its stake in shares of Bristol Myers Squibb by 2.5% during the third quarter. Boltwood Capital Management now owns 7,107 shares of the biopharmaceutical company’s stock valued at $443,000 after acquiring an additional 170 shares in the last quarter. KCM Investment Advisors LLC lifted its holdings in Bristol Myers Squibb by 0.8% during the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock worth $1,126,000 after buying an additional 174 shares during the last quarter. Sandy Cove Advisors LLC boosted its holdings in Bristol Myers Squibb by 4.7% in the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock worth $227,000 after purchasing an additional 176 shares during the period. Investment Research Partners LLC boosted its holdings in shares of Bristol Myers Squibb by 1.4% in the 4th quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock valued at $708,000 after buying an additional 179 shares during the period. Finally, Key Financial Inc raised its stake in Bristol Myers Squibb by 2.4% during the first quarter. Key Financial Inc now owns 7,939 shares of the biopharmaceutical company’s stock worth $482,000 after acquiring an additional 183 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
BMY has been the topic of several recent research reports. Piper Sandler reissued an “overweight” rating and issued a $82.00 price target (up from $75.00) on shares of Bristol Myers Squibb in a report on Wednesday, September 16th. Morgan Stanley restated an “underweight” rating and set a $41.00 price target (up from $40.00) on shares of Bristol Myers Squibb in a research report on Wednesday. Guggenheim reaffirmed a “buy” rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Finally, Raymond James Financial assumed coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “strong-buy” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $66.72.
Bristol Myers Squibb Stock Down 0.5%
Shares of NYSE BMY traded down $0.31 during mid-day trading on Thursday, reaching $59.39. 3,667,516 shares of the company traded hands, compared to its average volume of 11,966,175. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The stock has a market cap of $121.31 billion, a PE ratio of 13.08, a price-to-earnings-growth ratio of 0.28 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The company’s fifty day moving average is $64.38 and its two-hundred day moving average is $60.27.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same period in the prior year, the firm earned $1.46 EPS. Bristol Myers Squibb’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.
Bristol Myers Squibb Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be issued a $0.63 dividend. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is 55.51%.
Insider Transactions at Bristol Myers Squibb
In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.05% of the stock is owned by corporate insiders.
More Bristol Myers Squibb News
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: Positive Phase 3 Zenbexustm data: Bristol Myers Squibb reported that Zenbexus (iberdomide), combined with daratumumab and dexamethasone, delivered superior progression-free survival versus standard of care in relapsed and refractory multiple myeloma. The result strengthens BMY’s pipeline and could support a future growth driver in a competitive market. Bristol Myers Squibb Announces Zenbexus Phase 3 Results
- Positive Sentiment: Growth from newer medicines: Reblozyl’s strong sales and additional indications may help offset declines from older products. BMY also secured a Camzyos label expansion, potentially broadening the drug’s commercial opportunity. Reblozyl Growth Outlook
- Neutral Sentiment: Sotyktu adoption is developing unevenly: Rheumatologists are increasingly using the oral TYK2 inhibitor for psoriatic arthritis and recognize its differentiation, but limited experience, access hurdles and questions about joint efficacy are restraining its launch momentum. Sotyktu Psoriatic Arthritis Adoption
- Negative Sentiment: Analyst price-target reduction: Cantor Fitzgerald lowered its BMY target from $59 to $53 and maintained a neutral rating, signaling limited near-term upside in its view.
- Negative Sentiment: Patent-cliff concerns remain: Analysts continue to highlight the risk that patent expirations and declining legacy-drug sales could pressure revenue, increasing the importance of successful launches and pipeline development. Bristol Myers Squibb Patent Cliff Analysis
Bristol Myers Squibb Company Profile
Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.
Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.
Featured Articles
- Five stocks we like better than Bristol Myers Squibb
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
- This Space ETF Offers SpaceX Exposure—But Investors Are Paying for the Volatilit
- Does Lemonade’s Growth Signal Profits Ahead?
- These 3 ETFs Could Benefit From the Parts of Inflation That Won’t Go Away
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
